Vertex Pharma (VRTX) Tops Q1 EPS by 29c, Revenues Beat

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $2.98, $0.29 better than the analyst estimate of $2.69. Revenue for the quarter came in at $1.72 billion versus the consensus estimate of $1.66 billion.

"In CF, our goal is that all eligible patients have access to and can benefit from CFTR modulators. In the first quarter, we continued to make significant progress towards this goal, and in so doing again delivered strong revenue and earnings growth,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "Beyond CF, we have also seen continued significant progress across our broad pipeline, including advancement of VX-548 to Phase 2 in acute pain, initiation of the Phase 1/2 clinical trial with VX-880 in type 1 diabetes and completion of enrollment and dosing in our Phase 2 proof-of-concept study with the AAT corrector, VX-864. The recent amendment of our agreement with CRISPR Therapeutics for the CTX001 program further enhances our leadership position in cell and genetic therapies and we look forward to completing enrollment of our ongoing trials for CTX001 in sickle cell disease and beta thalassemia this year and bringing this first-in-class treatment to patients with these devastating diseases as soon as possible.”

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
• Crown Castle (CCI) Issues Statement on "Ted Miller's Latest Attempt to Disrupt the Company's Momentum"
• Growth isn't weak enough to truly undercut inflation pressures - BMO